[go: up one dir, main page]

AR021296A1 - Un anticuerpo humanizado especifico para 4-1bb humano y composiciones farmaceuticas que lo comprenden - Google Patents

Un anticuerpo humanizado especifico para 4-1bb humano y composiciones farmaceuticas que lo comprenden

Info

Publication number
AR021296A1
AR021296A1 ARP990105833A ARP990105833A AR021296A1 AR 021296 A1 AR021296 A1 AR 021296A1 AR P990105833 A ARP990105833 A AR P990105833A AR P990105833 A ARP990105833 A AR P990105833A AR 021296 A1 AR021296 A1 AR 021296A1
Authority
AR
Argentina
Prior art keywords
human
antibody
humanized antibody
understand
pharmaceutical compositions
Prior art date
Application number
ARP990105833A
Other languages
English (en)
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of AR021296A1 publication Critical patent/AR021296A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente está dirigida a anticuerpos humanizados que ligan específicamente la proteína 4-1BB. Los anticuerpos pueden ser producidos injertando lasregiones que determinan la complementaridad (CDRs) del anticuerpo monoclonal de raton para 4-1BB humano en las porciones remanentes de un anticuerpo humano yefectuando reemplazos adicionales de aminoácidos. Además, puede producirse una composicion farmacéutica que incluye el anticuerpo humanizado, la que puede serusada para tratar enfermedades autoinmunes y para suprimir una respuesta inmune. El anticuerpo humanizado de la presente tiene una afinidad elevada para 4-1BBhumano, y exhibe similitud de secuencias con el anticuerpo humano. Como resultado, la composicion farmacéutica de la presente puede ser usada para tratarenfermedades autoinmunes y para actuar como un inmunosupresor en humanos sin muchos efectos laterales.
ARP990105833A 1998-11-17 1999-11-17 Un anticuerpo humanizado especifico para 4-1bb humano y composiciones farmaceuticas que lo comprenden AR021296A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19980049177 1998-11-17
KR1019990016750A KR20000034847A (ko) 1998-11-17 1999-05-11 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물

Publications (1)

Publication Number Publication Date
AR021296A1 true AR021296A1 (es) 2002-07-03

Family

ID=26634340

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105833A AR021296A1 (es) 1998-11-17 1999-11-17 Un anticuerpo humanizado especifico para 4-1bb humano y composiciones farmaceuticas que lo comprenden

Country Status (12)

Country Link
US (1) US6458934B1 (es)
EP (1) EP1131357A1 (es)
JP (1) JP2002531383A (es)
KR (2) KR20000034847A (es)
CN (1) CN1187374C (es)
AR (1) AR021296A1 (es)
AU (1) AU757760B2 (es)
CA (1) CA2351170A1 (es)
CO (1) CO5160384A1 (es)
PE (1) PE20001316A1 (es)
TW (1) TWI230163B (es)
WO (1) WO2000029445A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
IL127127A0 (en) * 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CA2392477A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
KR100468321B1 (ko) * 2001-02-08 2005-01-27 학교법인 울산공업학원 종양 및 에이즈치료용 폴리펩타이드
ATE435655T1 (de) 2001-10-09 2009-07-15 Mayo Foundation Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
KR100452954B1 (ko) * 2002-02-26 2004-10-14 주식회사 엘지생명과학 가변영역 아미노산 치환을 통한 인간 4-1비비분자에 대한결합 특이성이 증가된 변형 인간화 항체의 제조방법
US20050222060A1 (en) * 2002-03-15 2005-10-06 Bot Adrian L Compositions and methods to initiate or enhance antibody and major-histocompatibility class I or class II-restricted t cell responses by using immunomodulatory, non-coding rna motifs
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
US20070037769A1 (en) * 2003-03-14 2007-02-15 Multicell Immunotherapeutics, Inc. Compositions and methods to treat and control tumors by loading antigen presenting cells
CN1688603A (zh) * 2002-07-15 2005-10-26 马约医学教育与研究基金会 使用4－1bb结合剂的治疗和预防
US6887673B2 (en) * 2002-07-30 2005-05-03 Bristol-Myers Squibb Company Humanized antibodies against human 4-1BB
JP2006508056A (ja) 2002-08-28 2006-03-09 イミュネックス・コーポレーション 心臓血管疾患を治療するための組成物および方法
CN1795274A (zh) * 2003-03-26 2006-06-28 多单元免疫治疗公司 诱导细胞死亡和/或凋亡的选定的rna基序
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
ES2671893T3 (es) 2004-10-06 2018-06-11 Mayo Foundation For Medical Education And Research B7-H1 y PD-1 en el tratamiento del carcinoma de células renales
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
RU2431638C2 (ru) * 2005-02-10 2011-10-20 Бэйлор Рисерч Инститьют Моноклональные антитела против интерферона-альфа и способы применения
EP1851244A4 (en) * 2005-02-15 2009-04-15 Gtc Biotherapeutics Inc ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF CANCER, AND GLYCOSYLATION VARIANTS THEREOF
US20060182744A1 (en) * 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
KR20080068089A (ko) * 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
WO2009134389A2 (en) * 2008-05-01 2009-11-05 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
CN102083859B (zh) 2008-05-07 2014-09-17 阿哥斯医疗公司 人源化抗人干扰素-α抗体
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
ES2703056T3 (es) 2013-04-30 2019-03-06 Univ Konkuk Ind Coop Corp Vector de direccionamiento de CMP-ácido acetilneuramínico hidroxilasa, animal transgénico para xenotrasplante introducido con el vector, y método de fabricación del mismo
WO2015050663A1 (en) 2013-10-01 2015-04-09 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of bim
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
WO2015179654A1 (en) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
WO2016014148A1 (en) 2014-07-23 2016-01-28 Mayo Foundation For Medical Education And Research Targeting dna-pkcs and b7-h1 to treat cancer
EP3354661B1 (en) * 2015-09-22 2020-06-03 Dingfu Biotarget Co., Ltd. Fully human antibody against human cd137 and use thereof
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
EP3544628A4 (en) * 2016-11-23 2020-11-18 Immunoah Therapeutics, Inc. 4-1BB BINDING PROTEINS AND THEIR USES
CA3039772C (en) 2017-01-06 2020-08-25 Eutilex Co., Ltd. Anti-human 4-1bb antibodies and uses thereof
KR102725761B1 (ko) 2017-01-20 2024-11-04 하이델베르크 파마 리서치 게엠베하 Cd137+ 세포의 고갈을 위한 조성물 및 방법
CN111511762B (zh) * 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
AU2018348431B2 (en) 2017-10-10 2025-10-02 Numab Therapeutics AG Antibodies targeting CD137 and methods of use thereof
EP3470428A1 (en) * 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting cd137 and methods of use thereof
CN109651507B (zh) * 2017-10-12 2021-11-26 瑞阳(苏州)生物科技有限公司 一种激动型4-1bb单克隆抗体
WO2019109238A1 (en) 2017-12-05 2019-06-13 Lyvgen Biopharma Co., Ltd. Anti-cd137 antibodies and uses thereof
RU2020127196A (ru) * 2018-01-22 2022-02-24 Цзянсу Хэнжуй Медицин Ко., Лтд. Антитело против 4-1bb, его антигенсвязывающий фрагмент и его медицинское применение
CN108195815A (zh) * 2018-01-31 2018-06-22 李翀 时间分辨荧光免疫层析法检测amh的试纸条、试剂盒及方法
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
US11993655B2 (en) * 2018-04-09 2024-05-28 Oricell Therapeutics Co., Ltd. Anti-PD-L1 antibody and use thereof
CN112867733B (zh) * 2018-10-19 2023-01-06 苏州丁孚靶点生物技术有限公司 抗cd137抗体及其应用
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
EP3906056A4 (en) * 2019-01-02 2023-02-08 QLSF Biotherapeutics Inc. CD137 AGONIST ANTIBODIES AND USES THEREOF
EP3966252A4 (en) * 2019-05-10 2023-01-25 Lyvgen Biopharma Holdings Limited HUMANIZED ANTI-CD137 ANTIBODIES AND THEIR USES
CN112794905B (zh) * 2019-11-13 2022-10-04 合肥瀚科迈博生物技术有限公司 一种能够与人4-1bb结合的分子
CN117843786A (zh) * 2019-11-19 2024-04-09 非同（成都）生物科技有限公司 人源化4-1bb单克隆抗体及其药物组合物
CN113004415B (zh) * 2019-12-19 2022-09-30 合肥瀚科迈博生物技术有限公司 靶向her2和4-1bb的双特异性抗体及其应用
CN113004416B (zh) * 2019-12-19 2022-10-04 合肥瀚科迈博生物技术有限公司 靶向her2-cd137双特异性抗体的构建及其应用
KR20230119179A (ko) * 2020-12-10 2023-08-16 우시 바이올로직스 아일랜드 리미티드 P-캐드히린에 대한 항체 및 이의 용도
CN112538116B (zh) * 2020-12-24 2022-11-25 东大生物技术(苏州)有限公司 一组4-1bb单克隆抗体及其医药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1996029348A1 (en) * 1995-03-23 1996-09-26 Indiana University Foundation Monoclonal antibody against human receptor protein 4-1bb and methods of its use for treatment of diseases
US5928893A (en) * 1995-04-08 1999-07-27 Lg Chemical Ltd. Monoclonal antibody specific for human 4-1BB and cell line producing same
JP2001502325A (ja) * 1996-10-11 2001-02-20 ブリストル―マイヤーズ・スクイブ・カンパニー 免疫調整の方法および組成物
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies

Also Published As

Publication number Publication date
CN1357009A (zh) 2002-07-03
AU757760B2 (en) 2003-03-06
CO5160384A1 (es) 2002-05-30
AU1186900A (en) 2000-06-05
EP1131357A1 (en) 2001-09-12
TWI230163B (en) 2005-04-01
US6458934B1 (en) 2002-10-01
KR20000034847A (ko) 2000-06-26
WO2000029445A1 (en) 2000-05-25
CA2351170A1 (en) 2000-05-25
PE20001316A1 (es) 2001-01-19
KR20010101022A (ko) 2001-11-14
CN1187374C (zh) 2005-02-02
JP2002531383A (ja) 2002-09-24

Similar Documents

Publication Publication Date Title
AR021296A1 (es) Un anticuerpo humanizado especifico para 4-1bb humano y composiciones farmaceuticas que lo comprenden
Bilej et al. Identification of a cytolytic protein in the coelomic fluid of Eisenia foetida earthworms
PE20230389A1 (es) Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
PE20050925A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
CY1118063T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΑΝΘΡΩΠ1ΝΗΣ IgE ΥΨΗΛΗΣ ΣΥΓΓΕΝΕΙΑΣ
EA201992755A1 (ru) Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4)
BR112022001368A2 (pt) Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
AR033978A1 (es) Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas
BG61095B2 (en) Humanized immunoglobulins, their preperation and application
KR960704576A (ko) CD40에 대한 항체(Antibodies to CD40)
RU2018120695A (ru) Связывающие молекулы, специфичные в отношении asct2, и их применения
EA202091747A1 (ru) Составы антитела b7-h4
PE20030282A1 (es) Anticuerpos de interleucina-1- beta
BR112022005044A2 (pt) Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
BR112021017046A2 (pt) Receptores de antígeno quiméricos antirreceptores de folato 1 humanizados e seus usos
CL2024002975A1 (es) Anticuerpo biespecífico anti-tigit y anti-pvrig, composición farmacéutica del mismo, y uso del mismo
PE20230682A1 (es) Anticuerpo anti-ox40 y usos del mismo
AR126001A1 (es) Anticuerpos y composiciones anti-nkg2a
Kaur et al. Evolution bites—timeworn inefficacious snakebite therapy in the era of recombinant vaccines
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
DK0493446T3 (da) Behandling af autoimmunsygdom.
KR940006602A (ko) 면역글로불린 이소타입에 대한 재조형 모노클로날 항체
Calvete et al. Antivenomics: a proteomics tool for studying the immunoreactivity of antivenoms
PE52996A1 (es) FRAGMENTO mAb MONOVALENTE (fab) DE mAb QUE TIENE LA CAPACIDAD DE REDUCIR LA SENSIBILIDAD DE LA EXPRESION DEL HLA-DR EN CELULAS PRESENTADORAS DEL ANTIGENO
Gomez-Robles et al. Antibodies against a single fraction of Micrurus dumerilii venom neutralize the lethal effect of whole venom

Legal Events

Date Code Title Description
FB Suspension of granting procedure